In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae
1
Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
2
Division of Infectious Diseases, Hartford Hospital, Hartford, CT 06102, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Lawrence S. Young
Pathogens 2015, 4(3), 620-625; https://doi.org/10.3390/pathogens4030620
Received: 7 July 2015 / Revised: 30 July 2015 / Accepted: 12 August 2015 / Published: 18 August 2015
Abstract
We evaluated the in vitro potency of cefepime combined with AAI101, a novel extended-spectrum β-lactamase inhibitor, against a population of clinical Escherichia coli and Klebsiella pneumoniae collected from USA hospitals. Of the 223 cefepime non-susceptible isolates, 95% were ceftazidime non-susceptible, 49% ertapenem non-susceptible, 57% piperacillin/tazobactam non-susceptible, 90% were multidrug-resistant (resistant to ≥3 drug classes), 22% produced carbapenemases, and 67% produced ESBLs. Addition of AAI101 restored the activity of cefepime such that the MIC50 was reduced from >64 mg/L for cefepime to 0.13 mg/L for cefepime/AAI101, supporting its continued development treatment for infections caused by these organisms. View Full-Text
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Crandon, J.L.; Nicolau, D.P. In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae. Pathogens 2015, 4, 620-625.
Related Articles
Article Metrics
Comments
[Return to top]
Pathogens
EISSN 2076-0817
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert